Trevi Therapeutics stock snapshot after recent moves

Trevi Therapeutics (TRVI) has drawn investor attention after recent share price moves, with the stock last closing at US$18.12. The company focuses on clinical-stage treatments targeting chronic cough and related respiratory conditions.

The recent 3.34% 1 day share price return and 8.05% 7 day share price return at Trevi Therapeutics sits against a 52.40% year to date share price return and a very large 5 year total shareholder return. This signals momentum that investors appear to be reassessing in light of the company’s clinical progress and risk profile.

If Trevi’s move has you rethinking opportunities in healthcare related stocks, it can help to see what else is gaining attention through the 41 healthcare AI stocks

After a sharp run and a current share price of US$18.12, some investors will see Trevi Therapeutics as gathering momentum, while others may prefer to wait for a pullback. So how does the current valuation stack up?

Most Popular Narrative: 27.2% Undervalued

Against Trevi Therapeutics' last close at $18.12, the most widely followed narrative points to a fair value of $24.90 that hinges on long term margin assumptions and rich future earnings multiples.

Approximately US$188 million in cash, cash equivalents and marketable securities at year end 2025 with an indicated runway into 2028 funds top line data across key IPF, non IPF ILD and refractory chronic cough studies. This limits near term financing pressure and can support more controlled decision making around future capital structure, share count and potential earnings per share.

Want to see what sits behind that valuation gap? The narrative leans on ambitious revenue ramp up, rising profit margins and a future earnings multiple that stands out from typical US pharmaceuticals peers.

The narrative uses a 7.11% discount rate and builds a path from zero reported revenue today to positive earnings, with profit margins moving toward the wider US pharmaceuticals sector over time. It also factors in rising share count and a very high future P/E on projected earnings by 2029, which together support the fair value estimate of $24.90 for Trevi Therapeutics.

Result: Fair Value of $24.90 (UNDERVALUED)

However, Trevi Therapeutics relies heavily on Haduvio, so any clinical setback or higher-than-expected share dilution from future capital raises could quickly challenge this undervaluation story.

Another view on Trevi Therapeutics valuation

The earlier narrative leans on long term earnings power to suggest Trevi Therapeutics looks undervalued. Yet on a simple P/B measure, the stock trades at 14.9x, which is far higher than both the US pharmaceuticals industry at 2.5x and its peer group at 5.4x. That sort of gap can leave less room for error if expectations have to reset.

For investors weighing these mixed signals, it is worth seeing what the numbers imply for risk and upside in plain terms, and how far sentiment would need to shift for the P/B ratio to move closer to a level the market might see as a fair ratio over time. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals around Trevi Therapeutics, it helps to see whether the market concerns showing up in the risk checks match your own view. Take a closer look at the 4 important warning signs.

Looking for more investment ideas beyond Trevi Therapeutics?

If Trevi Therapeutics has caught your interest, do not stop there. A few minutes with a focused stock list can surface opportunities you might wish you had seen earlier.

• Target potential value by reviewing companies flagged as attractively priced with solid fundamentals through the 51 high quality undervalued stocks.
• Strengthen your income focus by checking out businesses highlighted for resilient payouts in the 8 dividend fortresses.
• Prioritise capital preservation by scanning companies assessed for sturdier finances using the 84 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.